Allergy Immunotherapy denied as not medically necessary by Humana?

Humana's specific coverage criteria for allergy immunotherapy are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies Allergy Immunotherapy for "Medical Necessity" — and Why You Can Appeal

Medical necessity denials for allergy immunotherapy typically occur because Humana's reviewer determined that the submitted documentation did not adequately establish that the patient's condition meets the clinical criteria required under Humana's coverage policy — for example, that documented allergic sensitization is present, that symptoms are of sufficient severity and duration, that environmental controls and pharmacotherapy have been adequately trialed, or that the prescribing provider is an appropriate specialist. The good news: medical necessity denials are highly dependent on documentation quality, and a well-constructed appeal with complete records frequently reverses them.

## Federal Appeal Rights

• ACA Section 2719 external review: available for most individual and employer-sponsored plans; the filing window is approximately four months from the denial notice. An independent review organization — not Humana — makes the final call.
• ERISA Section 503 (employer plans): entitles you to a complete written statement of the specific medical necessity criteria that were not met, along with the clinical basis for the reviewer's conclusion.
• Expedited review is available if immunotherapy delay causes clinical harm (e.g., severe allergic asthma poorly controlled on maximum pharmacotherapy).

## Concrete Appeal Steps and Timeline

1. Request the denial letter in full — it must identify the specific criteria not met and the clinical reviewer's rationale. 2. Have your allergist review the denial letter and identify any documentation gap. 3. File a Level 1 internal appeal with a complete, organized record package. 4. If upheld, request a Level 2 peer-to-peer review between your allergist and Humana's medical reviewer (Humana is required to make this available in most states). 5. If still upheld, file for external review.

## Documentation to Gather

• Allergy testing records (skin-prick or specific IgE results) confirming clinically relevant sensitization to the allergens to be treated
• Symptom history: duration, frequency, impact on daily activities, and prior management attempts
• Treatment trial records: documentation of prior pharmacotherapy (antihistamines, nasal steroids, leukotriene modifiers) with dates, doses (from pharmacy records), and clinical outcomes
• Specialist evaluation: a complete note from the treating allergist or immunologist explaining the diagnosis, severity classification, and clinical rationale for immunotherapy
• Medical necessity letter: a detailed letter from the prescribing allergist mapping the patient's specific chart findings to each criterion in Humana's published allergy immunotherapy coverage policy

## Criteria-Mapping Structure

Locate Humana's allergy immunotherapy clinical policy (available on Humana's website under Clinical Coverage Policies). For each required criterion, create a one-to-one mapping:

| Humana Criterion (from policy) | Chart Documentation Supporting It | |---|---| | Confirmed IgE-mediated sensitization | Allergy test results with date | | Diagnosis: allergic rhinitis / asthma / venom hypersensitivity | Chart diagnosis + specialist note | | Prior pharmacotherapy trialed and outcome | Pharmacy records + progress notes | | Prescribing provider qualifications | Allergist / immunologist credentials |

Your appeal letter should quote Humana's exact criterion language, then immediately cite the chart evidence that satisfies it. Reviewers and external arbiters respond best to direct, point-by-point mapping rather than general narrative.